Methods for diagnosing RCC and other solid tumors

Details Methods for diagnosing RCC and other solid tumors Methods for diagnosing RCC and other solid tumors

2003-11-21

2009-11-03

Liu, Sue (Department: 1639)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C536S023100

Reexamination Certificate

active

07611839

ABSTRACT:
Methods, systems and equipment for diagnosing renal cell carcinoma (RCC) and other solid tumors. This invention identifies numerous disease genes that are differentially expressed in the peripheral blood of patients having RCC or other solid tumors relative to disease-free humans. These disease genes can be used as surrogate markers for detecting the presence or absence of RCC or other solid tumors.

REFERENCES:
patent: 4489710 (1984-12-01), Spitler
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4569789 (1986-02-01), Blattler et al.
patent: 4625014 (1986-11-01), Senter et al.
patent: 4638045 (1987-01-01), Kohn et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4751180 (1988-06-01), Cousens et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 5459039 (1995-10-01), Modrich et al.
patent: 5498531 (1996-03-01), Jarrell
patent: 5840506 (1998-11-01), Giordano
patent: 5919619 (1999-07-01), Tullis
patent: 6087098 (2000-07-01), McKiernan et al.
patent: 6110675 (2000-08-01), Cohen et al.
patent: 6190857 (2001-02-01), Ralph et al.
patent: 6288220 (2001-09-01), Kambara et al.
patent: 6303301 (2001-10-01), Mack et al.
patent: 6317731 (2001-11-01), Luciano
patent: 6391562 (2002-05-01), Kambara et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6647341 (2003-11-01), Golub et al.
patent: 2001/0053548 (2001-12-01), Rybak et al.
patent: 2002/0042072 (2002-04-01), Van Meel
patent: 2002/0132274 (2002-09-01), Nevalainen et al.
patent: 2002/0164664 (2002-11-01), Hlavaty et al.
patent: 2002/0168638 (2002-11-01), Schlegel et al.
patent: 2002/0182614 (2002-12-01), Gillis et al.
patent: 2004/0175743 (2004-09-01), Burczynski et al.
patent: 2004/0235020 (2004-11-01), Burczynski et al.
patent: WO 89/10134 (1989-11-01), None
patent: WO 97/07668 (1997-03-01), None
patent: WO 97/07669 (1997-03-01), None
patent: WO 99/14346 (1999-03-01), None
patent: WO 99/27132 (1999-06-01), None
patent: WO00/40749 (2000-07-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/63364 (2000-10-01), None
patent: WO 01/29058 (2001-04-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/68836 (2001-09-01), None
patent: WO 01/70949 (2001-09-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO01/81916 (2001-11-01), None
patent: WO 01/92513 (2001-12-01), None
patent: WO 02/08399 (2002-01-01), None
patent: WO 02/24924 (2002-03-01), None
patent: WO02/40000 (2002-05-01), None
patent: WO 02/40717 (2002-05-01), None
patent: WO03/032813 (2003-04-01), None
patent: WO2004/048933 (2004-06-01), None
patent: WO2004/072265 (2004-08-01), None
patent: WO 2004/072265 (2004-08-01), None
patent: WO 2004/094673 (2004-11-01), None
patent: WO 2004/097052 (2004-11-01), None
Olive et al. Expression of cytokine mRNA transcripts in renal cell carcinoma. Immunology and Cell Biology. vol. 76: 357-362. 1998.
Golub et al. Molecular classfication of cancer: class discovery and class prediction by gene expression monitoring. Science. vol. 286: 531-537. 1999.
Liu et al. Upregulation of Toll-like receptor 2 gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is involved in NG-kB Activation. Infection and Immunity. vol. 69: 2788-2796. 2001.
Mayo et al., Biochimica et Biophysica Acta. vol. 1470: M55-M62; 2000.
GenBank Printout, (http://www.ncbi.nih.gov/Genbank/index.html), “Updating or Revising a Sequence”; downloaded Feb. 21, 2007.
UNIGENE Printout, “Hs.63668”; downloaded Feb. 21, 2007.
Anand et al., Nature Genetics. Voll. 31: 301-305; 2002.
Young et al., American Journal of Pathology. vol. 158(5): 1639-1651; May 2001.
Palsson-McDermott et al., Ir J. Med. Sci. vol. 176: 253-260; 2007.
El-Omar et al., Oncogene. vol. 27: 244-252; 2008.
Thornton et al., J. Mol. Med. vol. 81: 536-548; 2003.
U.S. Appl. No. 60/427,982, Burczynski. M. et al.
U.S. Appl. No. 60/459,782, Twine, N. C. et al.
U.S. Appl. No. 60/446,133, Burczynski. M. et al.
U.S. Appl. No. 60/538,246, Burczynski. M. et al.
U.S. Appl. No. 60/466,067, Dorner, A. et al.
Burczynski et al., “Pharmacogenomic expression profiling of renal cell carcinoma in a phase II trial of CCI-779: identification of surrogate markers of disease and predictors of outcome in the compartment of peripheral blood”,European Journal of Cancer, Pergamon Press, Oxford, GB, vol. 38, Nov. 11, 2002, p. S51.
Schulze-Koops, H. et al., “Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1)”,Clinical and Experimental Immunology, vol. 106, No. 2, Nov. 1996, pp. 190-196.
Dipaola, R.S., et al., “Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies,”Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 17, No. 7, Jul. 1999, pp. 2213-2218.
“Product Catalogue”, Jan. 2001,Affymetrix, p. 1.
Lichtenfels, R. et al., “Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses”,Biochimica et Biophysica Acta, vol. 1646, No. 1-2, Mar. 21, 2003, pp. 21-31.
Su, Andrew I., et al., “Large-scale analysis of the human and mouse transcriptomes,”Proceedings of the National Academy of Sciences of the United States of America, vol. 99, No. 7, Apr. 2, 2002, pp. 4465-4470.
Database Source Online!, http://genome-www5.stanford.edu/cgi-bin/source/expressionSearch?option=cluster&criteria=Hs. 171501&organism=Hs abstract.
Elit, Laurie, “CCI-779 Wyeth,”Current Opinion in Investigational Drugs(London, England: 2000), vol. 3, No. 8, Aug. 2002, pp. 1249-1253.
Peralba, Josep Maria, et al., “Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients,”Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 9, No. 8, Aug. 1, 2003, pp. 2887-2892.
Rininger, J., et al., “Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity”,Drug Discovery Today United Kingdom, vol. 5, No. 12, Dec. 1, 2000, pp. 560-568.
PCT International Search Report; PCT/US2004/006601; Nov. 19, 2004; 4 pages.
Deprimo et al., “Expression Profiling of Blood Samples from an SU5416 Phase III Metastatic Colorectal Cancer Clinical Trial: a Novel Strategy for Biomarker Identification”, Biomed Central, pp. 1471-2407.
Altschul et al.; “Gapped Blast and PSI-Blast: a New Generation of Protein Database Search Programs”, Nucleic Acids Research, 1997, pp. 3389-3402, vol. 25, No. 17, Oxford University Press.
Berger P. et al.; “Loss of Phosphatase Activity in Myotubularin-Related Protein 2 is Associated With Charcot-Marie Tooth Disease Type 4BI”, Human Molecular Genetics, 2002, pp. 1569-1579, vol. 11, No. 13, Oxford University Press.
Boe R. et al.; “The Protein Phosphatase Inhibitor Okadaic Acid Induces Morphological Changes Typical of Apoptosis in Mammalian Cells”, Experimental Cell Research 195, 1991, pp. 237-246, Academic Press, Inc.
Bottini N. et al.; “Low-Molecular-Weight Protein Tyrosine Phosphatase and Human Disease: in Search of Biochemical Mechanisms”, Archivum Immunologiae Et Therapiae Experimentalis, 2002 pp. 95-104, vol. 50.
Brown-Shimer, et al.; “Effect of Protein Tyrosine Phosphatase 1b Expression on Transformation by the Human neu Oncogene”, Cancer Research, 52, 1992, pp. 478-548.
Chen et al.; “The Myotonic Dystrophy Kinase-Related Cdc42-Binding Kinase is Involved in the Regulation of Neurite Outgrowth in PC12 Cells”, The Journal of Biological Chemistry 1999, pp. 19901-19905, vol. 274, No. 28, The American Society for Biochemistry and Molecular Biology, Inc.
Delagrave et al.; “Recursive Ensemble Mutagenesis”, Protein Engineering, 1993, pp. 327-331, vol. 6 No. 3, Oxford University Press.
Dong et al.; “Cdc42 Antagonizes Inductive Action o

Affiliated with

Also associated with

Rating

Methods for diagnosing RCC and other solid tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for diagnosing RCC and other solid tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing RCC and other solid tumors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4096270